Olema Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, reported its financial results for the first quarter ending March 31, 2025. The company ended the quarter with $392.7 million in cash, cash equivalents, and marketable securities. The net loss for the quarter was $30.4 million, slightly improved from the $31.0 million net loss for the same period in 2024. This decrease in net loss was attributed to higher interest income earned from marketable securities, which was primarily offset by increased spending on clinical development and research activities due to late-stage clinical trials for palazestrant and the advancement of OP-3136. GAAP research and development (R&D) expenses rose to $30.6 million compared to $29.9 million in the previous year, driven by increased clinical operations and development-related activities. Non-GAAP R&D expenses were reported at $27.3 million, excluding a $3.3 million non-cash stock-based compensation expense. GAAP general and administrative (G&A) expenses decreased to $4.2 million from $4.5 million in the previous year. The company continues to advance its pivotal Phase 3 trials, including OPERA-02 and OPERA-01, for treatments related to metastatic breast cancer, with ongoing recruitment for a Phase 1 trial for OP-3136.